Soo-Ryum Yang, MD

Panelists discuss what they would like to see in future trials to address the unmet needs and challenges in treating patients diagnosed with lung large cell neuroendocrine carcinoma (LCNEC).

Panelists discuss any upcoming trials on the horizon that they are excited about in the context of lung large cell neuroendocrine carcinoma (LCNEC) treatment.

Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).

Panelists discuss ongoing trials with BI 764532 and their potential impact on the treatment of lung large cell neuroendocrine carcinoma (LCNEC).

Panelists discuss how novel targeted therapies, such as T-cell engagers, could improve outcomes for patients with lung large cell neuroendocrine carcinoma (LCNEC) and other neuroendocrine cancers (NECs).

Panelists discuss their impressions of the LANCE pilot study for atezolizumab in lung large cell neuroendocrine carcinoma (LCNEC) and its potential impact on treatment strategies.

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Panelists discuss the vital multidisciplinary coordination needed to optimize care for patients with lung large cell neuroendocrine carcinoma (LCNEC), including the roles of various specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the importance of involving the patient in these discussions.

Panelists discuss the challenges encountered with molecular or pathology testing for lung large cell neuroendocrine carcinoma (LCNEC) and how treatment plans are determined when testing is not feasible.

Panelists discuss the factors that influence the decision to perform a fine needle aspirate vs an incisional biopsy, whether testing is conducted in-house or at a central laboratory, and how the results of these tests impact the treatment plan for patients with lung large cell neuroendocrine carcinoma (LCNEC).

Panelists discuss how biomarker testing for lung large cell neuroendocrine carcinoma (LCNEC) is approached, covering the frequency and types of tests used, such as NGS, the timing of DLL3 testing, and the factors influencing the choice between fine needle aspirate and other biopsy techniques.

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is diagnosed, including the challenges associated with its differential diagnosis.

Panelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is characterized by its biology, incidence, risk factors, clinical presentation, and prognosis, while addressing the challenges, unmet needs, and the trial data required to guide testing and treatment guidelines for this rare cancer.